Free Trial

Hikma Pharmaceuticals (HIK) Competitors

Hikma Pharmaceuticals logo
GBX 1,953 +18.00 (+0.93%)
(As of 12/20/2024 12:01 PM ET)

HIK vs. HCM, INDV, AMYT, AGY, APH, BXP, ANCR, DNL, EAH, and STX

Should you be buying Hikma Pharmaceuticals stock or one of its competitors? The main competitors of Hikma Pharmaceuticals include HUTCHMED (HCM), Indivior (INDV), Amryt Pharma (AMYT), Allergy Therapeutics (AGY), Alliance Pharma (APH), Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Diurnal Group (DNL), ECO Animal Health Group (EAH), and Shield Therapeutics (STX). These companies are all part of the "drug manufacturers - specialty & generic" industry.

Hikma Pharmaceuticals vs.

Hikma Pharmaceuticals (LON:HIK) and HUTCHMED (LON:HCM) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, community ranking, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

Hikma Pharmaceuticals has a net margin of 9.45% compared to HUTCHMED's net margin of -6.87%. Hikma Pharmaceuticals' return on equity of 12.88% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
Hikma Pharmaceuticals9.45% 12.88% 9.40%
HUTCHMED -6.87%-5.44%-5.90%

Hikma Pharmaceuticals currently has a consensus price target of GBX 2,383.33, suggesting a potential upside of 22.03%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Hikma Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

42.1% of Hikma Pharmaceuticals shares are held by institutional investors. Comparatively, 36.5% of HUTCHMED shares are held by institutional investors. 30.5% of Hikma Pharmaceuticals shares are held by insiders. Comparatively, 39.0% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hikma Pharmaceuticals has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Hikma Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hikma Pharmaceuticals£3.02B1.43£285M£0.653,004.62
HUTCHMED£610.81M3.32-£41.97M-£0.04-5,925.00

In the previous week, Hikma Pharmaceuticals and Hikma Pharmaceuticals both had 1 articles in the media. Hikma Pharmaceuticals' average media sentiment score of 0.19 beat HUTCHMED's score of 0.00 indicating that Hikma Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Hikma Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
HUTCHMED
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Hikma Pharmaceuticals received 604 more outperform votes than HUTCHMED when rated by MarketBeat users. However, 78.40% of users gave HUTCHMED an outperform vote while only 70.55% of users gave Hikma Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Hikma PharmaceuticalsOutperform Votes
800
70.55%
Underperform Votes
334
29.45%
HUTCHMEDOutperform Votes
196
78.40%
Underperform Votes
54
21.60%

Hikma Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500.

Summary

Hikma Pharmaceuticals beats HUTCHMED on 13 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HIK vs. The Competition

MetricHikma PharmaceuticalsDrug Manufacturers IndustryMedical SectorLON Exchange
Market Cap£4.33B£1.15B£5.13B£1.84B
Dividend Yield3.25%3.04%5.08%10.58%
P/E Ratio3,004.62131.2389.581,771.92
Price / Sales1.431,962.971,116.12375,802.49
Price / Cash8.3410.1142.8227.86
Price / Book1.893.064.772.89
Net Income£285M£152.21M£120.15M£155.43M
7 Day Performance0.98%-0.48%-1.92%-1.91%
1 Month Performance4.33%-1.32%11.47%17.44%
1 Year Performance9.17%98.66%30.54%28.79%

Hikma Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HIK
Hikma Pharmaceuticals
1.5311 of 5 stars
GBX 1,953
+0.9%
GBX 2,383.33
+22.0%
+8.3%£4.33B£3.02B3,004.629,100News Coverage
HCM
HUTCHMED
N/AGBX 239
-3.2%
N/A-12.9%£2.04B£610.81M-6,150.001,760
INDV
Indivior
2.503 of 5 stars
GBX 950
+4.6%
GBX 1,500
+57.9%
-22.5%£1.22B£1.15B-1,135.001,000Analyst Forecast
AMYT
Amryt Pharma
N/AGBX 143
-11.7%
N/A+0.0%£457.11M£210.24M-4.33290Gap Down
AGY
Allergy Therapeutics
N/AGBX 6.40
+3.2%
N/A+190.9%£305.28M£53.26M-103.33612Gap Down
APH
Alliance Pharma
3.3023 of 5 stars
GBX 48.40
+0.4%
GBX 60
+24.0%
+15.2%£261.64M£183.15M-803.3391,000News Coverage
Positive News
BXP
Beximco Pharmaceuticals
N/AGBX 37.70
+7.7%
N/A-14.6%£168.18M£43.08B471.255,500News Coverage
Gap Up
ANCR
Animalcare Group
N/AGBX 240
-0.6%
N/A+35.9%£144.89M£76.10M3,023.13220
DNL
Diurnal Group
N/AGBX 27.30
flat
N/A+0.0%£46.33M£4.68M-3.2133
EAH
ECO Animal Health Group
N/AGBX 68.14
-2.7%
N/A-34.6%£46.16M£89.42M3,450.00234Gap Down
STX
Shield Therapeutics
N/AGBX 2.65
-1.7%
N/A-58.3%£20.75M£21.47M-68.0040,000

Related Companies and Tools


This page (LON:HIK) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners